-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The research and development of anti-coronavirus drugs is in a stage of vigorous development, and countries around the world are accelerating research
The data of Paroved in the phase II/III clinical randomized controlled double-blind trial EPIC-HR are eye-catching
AGILE-ACCORD is another multicenter, open-label, adaptive Phase I/II randomized platform trial based in the United Kingdom and South Africa
.
The results demonstrated that monopiravir was well tolerated at doses of 400 mg, 600 mg or 800 mg, with no serious adverse reactions
.
It is worth mentioning that the book "Quick Guide for Coronavirus Disease 2019: Managing COVID-19" published by NICE in March 2022 specifically mentioned that antiviral drugs include: Paloviride, Monopiravir Clinical efficacy evaluation of remdesivir, remdesivir and some neutralizing monoclonal antibodies
.
The latter is a cocktail of two monoclonal antibody drug combinations (Casirivimab and Imdevimab) used by former US President Trump to treat the new crown infection, and is a new anti-inflammatory drug of fully human monoclonal antibody against the interleukin-6 receptor
.
NICE analyzed various anti-new coronavirus drugs in terms of benefits and harms, fairness, acceptability, feasibility, rationality, main outcomes (hospitalization, death, side effects), viral load, and reliability of results.
Review comments
.
Finally, NICE's opinion on the health technology evaluation of monopiravir is only a conditional recommendation
.
In November 2021, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the drug for use in adult patients with mild and moderate COVID-19
.
Summary <<<
Dawoud et al.
published a cost-effectiveness analysis of antiviral drugs for respiratory disease pandemics in the journal Value in Health in November 2021, systematically searched 782 literature, including COVID-19 until July 2021 Literature on the pharmacoeconomics of viral infections, of which 14 met the inclusion criteria
.
In view of the collected literatures before the listing of parovide and monopiravir, so far there has been no public report on the economic evaluation of these two drugs, and further research is needed in the future
.
